About Event

There has been a huge boom of interest and investment in RNAi-based therapeutics due to their great potential to treat neurology, cardiology, oncology and more. For instance, Novo Nordisk has just announced their recent approval of RivflozaTM for the treatment of a rare genetic condition as well as Alnylam has shown promising results from a RNAi therapeutic treating Alzheimer’s disease.

Curated in collaboration with key opinion leaders, the 5th RNAi-Based Therapeutics Summit returned with a jam-packed 3-day agenda to overcome challenges within manufacturing, targeted delivery and siRNA efficacy to help advance RNAi therapies through the pipeline. The summit provided a vital opportunity to come together to discuss the bottlenecks of developing RNAi drugs and ensuring effective therapies get to patients faster.

Industry experts navigated through presentations and interactive discussions on:

Expand beyond the current druggable targets by evaluating the challenges of delivery to the CNS, skin and eyes and reveal the full potential of RNAi therapeutics with AbbVie, OliX Pharmaceuticals & NanoDe Therapeutics
Discuss novel delivery platforms and strategies to prevent rate limiting endosomal escape for successful and specific delivery of liver and non-liver targeting drugs with Alnylam Pharmaceuticals, Matinas BioPharma & Sapreme Technologies
Leverage novel chemical modifications to improve efficacy and stability of siRNAs for advancement of RNAi therapies with Silence Therapeutics & University of Massachusetts Chan Medical School
Analyze critical challenges of targeting oncological indications via RNAi drugs towards acceleration into the clinic of robust and effective anti-cancer treatments with Dicerna Pharmaceuticals & Transcode Therapeutics
Uncover successful production strategies and late-stage manufacturing bottlenecks to support and enable improved scale-up and fast-track the manufacturing processes with OliX Pharmaceuticals & Sirnaomics